Accurate prediction of the malignant potential of lung cancer, reflecting biological features, such as progression, invasiveness, and metastasis, is an important goal in clinical oncology. In lung cancer, however, and adenocarcinoma in particular, there are no reliable prognostic markers reported for immunohistochemical use, although several candidates have been recently, including oncogene products (Harada et al., 1992) , growth factors , proteinases , antiproteinases (Higashiyama et al., 1992) , and blood type expression (Lee et al., 1991) .
It has recently been recognised that the nm23 gene and its product are closely related to the metastatic potential of some tumour cells (Steeg et al., 1988; Liotta et al., 1991) . Low levels of nm23 mRNA and the corresponding protein have been reported to reflect high metastatic potential in both experimental animal tumours and human breast cancer (Steeg et al., 1988; Bevilacqua et al., 1989; Rosengard et al., 1989; Barnes et al., 1991; Liotta et al., 1991; Hennesy et al., 1991) . The expression of nucleoside diphosphate kinase (NDP kinase), which is now known to be identical to the nm23 gene product (Kimura & Shimada, 1988; Rosengard et al., 1989; Kimura et al., 1990; Wallet et al., 1990) , has been investigated in breast cancer by immunohistochemistry: the results suggest that the nm23 gene product/NDP kinase expression may possibly be a useful prognostic marker (Hirayama et al., 1991) . (Mountain, 1986) Immunohistochemistry was performed according to a modification of the method of Hsu et al. (1981) . Briefly, sections (4 jm thick) from each tissue block were deparaffinised, and endogenous peroxidase activity was blocked using 0.3% hydrogen peroxide in methanol. After treatment in 2% normal goat serum, they were incubated with specific antibody to NDP kinase (diluted 1:300), raised against the NDP kinase from rat liver (Kimura & Shimada, 1988) . The specificity of the antibody had been confirmed previously by immunoelectrophoretic blotting (Kimura & Shimada, 1988) , and this antibody is known to be suitable for immunohistochemical applications (Hirayama et al., 1991) . Sections were treated with biotinylated goat antirabbit IgG (Vector), and subsequently with avidin-biotin peroxidase complex (Vectastatin ABC kit, Vector).
The peroxidase reaction used 0.02%, 3,3'-diaminobenzidine tetrahydrochloride in 0.05 M TRIS buffer, pH 7.6, containing 0.01% hydrogen peroxide. ducts, and some bronchial epithelial often showed immunoreactivity for NDP kinase (Figure 1) .
Thirty-nine (44%) of 88 pulmonary adenocarcinoma patients belonged to Group B, and 49 (56%) to Group A. Figure 2a . The average 5-year survival rates were 63% in Group A and 42% in Group B (P = 0.15). Figure 2b shows that the average 5-year survival rates for stage I patients were 76% in Group A and 58% in Group B (P = 0.35). There was no significant difference in survival rates between the Groups.
Discussion
In the present study, in which we used an immunohistochemical technique with an antibody against rat NDP kinase, we demonstrated that there was no relationship between the extent of nm23 gene product/NDP kinase expression and the grade of malignancy in pulmonary adenocarcinoma. In particular, indicators of metastatic potential such as nodal involvement status appeared to be independent of this expression. Our results disagree with those of several previous breast cancer studies as well as studies of experimental tumours (Bevilacqua et al., 1989; Rosengard et al., 1989; Wallet et al., 1990; Barnes et al., 1991; Hennesy et al., 1991; Hirayama et al., 1991; Liotta et al., 1991) . Patients with high levels of NDP kinase expression unexpectedly included many rather advanced cases.
Similar results have been recorded in several other human malignancies. Aggressive neuroblastoma showed higher levels of nm23 gene protein with N-myc gene amplification (Hailat et al., 1991) . In colonic cancer, in contrast to the evidence of nm23 allelic gene deletions in aggressive cases (Cohen et al., 1991) , nm23 mRNA levels increased in both localised and metastatic disease (Haut et al., 1991) . In addition, Lacombe et al. (1991) recently showed that some human solid tumours, including breast cancer, overexpressed NDP kinase, irrespective of lymph node involvement. Our present data confirm that nm23 gene product/NDP kinase expression is not always associated with indicators of tumour malignancy such as metastatic potential or prognosis.
Currently, these discrepancies, regarding the significance of the nm23 gene product/NDP kinase expression in human malignancy, are not understood, but two explanations are suggested. First, the biological significance of NDP kinase expression may be quite different in different tissues. High levels of expression are associated with better prognosis in breast carcinoma (Hirayama et al., 1991) , and are also found in normal breast epithelium (Barnes et al., 1991) . In contrast, expression is in general lower in normal colonic epithelium than in carcinoma (Haut et al., 1991) , and we have also demonstrated the same situation in the lung by immunohistochemistry using the same antibody as Hirayama et al. (data not shown). Secondly, the nm23 gene product/NP kinase is now demonstrated to consist of two isotypes, nm23-H1 and nm23-H2 (Stahl et al., 1991) , which are identical with chain A and chain B of NDP kinase, respectively (Gilles et al., 1991) . The expression of the nm23-HI isotype is reduced in breast cancer with higher metastatic potential (Hennesy et al., 1991; Stahl et al., 1991) . Allelic loss of the nm23-HI gene on chromosome 17 is observed in pulmonary adenocarcinoma , but it is still unknown which type of predominant with regard to the metastatic potential of lung cancer. The antibody used in the present study may probably bind both types (Kimura, unpublished data). 
